Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Immune Checkpoint Inhibitors for Cancer in People With HIV

In a real-world study, the safety and efficacy of immune checkpoint inhibitors (ICIs) were similar when used for a variety of cancer types in people living with HIV (PWH) compared with people living without HIV (PWOH), researchers report.

The retrospective study included PWH treated with anti–[programmed death (PD)]-1- or anti–PD-L1–based therapies for advanced cancers. Using the Kaplan-Meier method to estimate overall survival (OS) and progression-free survival (PFS), the investigators found: “Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were [non-small-cell lung cancer (NSCLC)] (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month [restricted mean survival time] difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS.”

Source: Journal of Clinical Oncology